Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

NEWS

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia
X4 Pharmaceuticals (Nasdaq: XFOR) will host a virtual investor event on June 27, 2024, at 8:00 AM ET to present new interim results from a Phase 2 clinical trial on mavorixafor for treating chronic neutropenia (CN).
The webcast will showcase hematological data from at least 15 participants, treated either with mavorixafor monotherapy or in combination with G-CSF. Experts will provide insights on the clinical results and the high unmet need in CN treatment.
The company plans to start a global Phase 3 trial in the current quarter to assess the efficacy, safety, and tolerability of mavorixafor in patients with various types of CN facing recurrent infections. A Q&A session will follow the presentation.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
2
+0
5
Translate
Report
2827 Views
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
950Followers
63Following
6415Visitors
Follow